

LIGAND PHARMACEUTICALS INC
Form SC 13G/A
February 08, 2012

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 4)*

Ligand Pharmaceuticals Inc

(Name of issuer)

Common Stock
(Title of class of securities)

53220K504
(CUSIP number)

December 30, 2011
(Date of event which requires filing of this statement)

Edgar Filing: LIGAND PHARMACEUTICALS INC - Form SC 13G/A

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13G

CUSIP No. 53220K504

Page 2 of 5 Pages

(1) Names of reporting persons

UBS AG directly and on behalf of certain subsidiaries

(2) Check the appropriate box if a member of a group (see instructions)

(a) (b)

(3) SEC use only

(4) Citizenship or place of organization

Switzerland

(5) Sole voting power

Number of

shares 38,600
(6) Shared voting power

beneficially

owned by 0
each (7) Sole dispositive power

reporting

person 38,600
(8) Shared dispositive power

with:

0

(9) Aggregate amount beneficially owned by each reporting person

38,600

(10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions)

Edgar Filing: LIGAND PHARMACEUTICALS INC - Form SC 13G/A

(11) Percent of class represented by amount in Row (9)

.20%

(12) Type of reporting person (see instructions)

BK

SCHEDULE 13G

CUSIP No. 53220K504

Page 3 of 5 Pages

Item 1(a) Name of Issuer
Ligand Pharmaceuticals Inc

Item 1(b) Address of Issuer's Principal Executive Offices:
11085 North Torrey Pines Road

La Jolla, California 92037

Item 2(a) Name of Person Filing:
UBS AG

Item 2(b) Address of Principal Business Office:
UBS AG

Bahnhofstrasse 45

PO Box CH-8021

Zurich, Switzerland

Item 2(c) Citizenship or Place of Organization:
Switzerland

Item 2(d) Title of Class of Securities
Common Stock

Item 2(e) CUSIP Number(s):
53220K504

Item 3. Type of Person Filing:
UBS AG is classified as a Bank as defined in section 3(a)(6) of the Securities Act of 1933 pursuant to no-action relief granted by the staff of the Securities and Exchange Commission.

Edgar Filing: LIGAND PHARMACEUTICALS INC - Form SC 13G/A

Item 4 (a)-(c)(iv). Ownership:

Items 5-11 of the cover page are incorporated by reference.

SCHEDULE 13G

CUSIP No. 53220K504

Page 4 of 5 Pages

Item 5. Ownership of Five Percent or Less of a Class:

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following x.

Item 6. Ownership of More than Five Percent on Behalf of Another Person:

Not applicable

Item 7. Identification and Classification of the Subsidiary That Acquired the Security Being Reported on By the Parent Holding Company:

This statement on Schedule 13G is being filed by UBS AG on behalf of itself and its wholly owned subsidiaries UBS AG London Branch, UBS Securities LLC, and UBS Financial Services Inc.

Item 8. Identification and Classification of Members of the Group

Not Applicable

Item 9. Notice of Dissolution of Group:

Not Applicable

Item 10. Certification:

By signing below, the undersigned certify that, to the best of their knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SCHEDULE 13G

CUSIP No. 53220K504
SIGNATURE

Page 5 of 5 Pages

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

By: /s/ Anthony DeFilippis
Executive Director

By: /s/ Gordon Kiesling
Executive Director

Date: February 8, 2012